Fri, May 8, 2020

Charles Duncan Reiterated (ACAD) at Buy with Increased Target to $63 on, May 8th, 2020

Charles Duncan of Cantor Fitzgerald, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $58 to $63 on, May 8th, 2020.

Charles has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 0 agree with Charles's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Charles


  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $60 on, Thursday, April 16th, 2020
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $72 on, Tuesday, March 31st, 2020
  • Neena Bitritto-Garg of "Citigroup" Initiated at Strong Buy and Held Target at $69 on, Friday, March 6th, 2020